An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

NCT06284226 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The project is terminated

Conditions

Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)

Interventions

DRUG: Allogeneic NK（CCT-ANK-11)

Sponsor

Beijing Kejing Biotechnology Co., Ltd.